Immune check-point in cervical cancer

•The risk of recurrent/metastatic cervical cancer represents a common entity.•The role of immune check-point inhibitors is being tested in cervical cancer.•This is the largest updated analysis of clinical trials in cervical cancer patients.•This analysis suggests that immune check-point inhibitors c...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Critical reviews in oncology/hematology 2018-09, Vol.129, p.40-43
Hauptverfasser:	De Felice, F., Marchetti, C., Palaia, I., Ostuni, R., Muzii, L., Tombolini, V., Benedetti Panici, P.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal - therapeutic use B7-H1 Antigen - antagonists & inhibitors Biomarkers - analysis Cervical cancer CTLA-4 CTLA-4 Antigen - antagonists & inhibitors Female Humans Immune check-point Immunotherapy Immunotherapy - methods Ipilimumab Nivolumab Patient Selection PD-1 Pembrolizumab Uterine Cervical Neoplasms - drug therapy Uterine Cervical Neoplasms - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!